BACKGROUND: To date, no evidence exists in the literature as to the effects of inhaled corticosteroids (ICs) on salivary composition in patients with bronchial asthma. OBJECTIVE: The aim of this study was to assess the effect of ICs on salival composition. METHODS: Adult patients attending an outpatient respiratory clinic who were classified into two groups (controls and patients with bronchial asthma receiving ICs), were recruited in this cross-sectional study. For each participant, data of clinical records, baseline history of asthma, and regular IC dose were recorded. A sample of stimulated saliva was collected and processed for investigation of mucin 5B (MUC5B), lipoxygenase (LPO), total antioxidant capacity, and 8-hydroxydeoxyguanosine (8-OHdG) levels. RESULTS: Overall, 103 patients (49 controls and 54 patients receiving regular treatment with ICs) were recruited. No differences in comorbidities or smoking habits were observed. Patients treated with high-doses of ICs showed lower levels of salival MUC5B compared with those treated with medium IC doses or those not treated with ICs (1.60 vs. 2.20 vs. 2.53 ng/mL; p = 0.042). CONCLUSION: In patients with asthma, treatment with high-doses of ICs is associated with reduced levels of salivary MUC5B. This effect can explain some of the effects of ICs on oral health.
BACKGROUND: To date, no evidence exists in the literature as to the effects of inhaled corticosteroids (ICs) on salivary composition in patients with bronchial asthma. OBJECTIVE: The aim of this study was to assess the effect of ICs on salival composition. METHODS: Adult patients attending an outpatient respiratory clinic who were classified into two groups (controls and patients with bronchial asthma receiving ICs), were recruited in this cross-sectional study. For each participant, data of clinical records, baseline history of asthma, and regular IC dose were recorded. A sample of stimulated saliva was collected and processed for investigation of mucin 5B (MUC5B), lipoxygenase (LPO), total antioxidant capacity, and 8-hydroxydeoxyguanosine (8-OHdG) levels. RESULTS: Overall, 103 patients (49 controls and 54 patients receiving regular treatment with ICs) were recruited. No differences in comorbidities or smoking habits were observed. Patients treated with high-doses of ICs showed lower levels of salival MUC5B compared with those treated with medium IC doses or those not treated with ICs (1.60 vs. 2.20 vs. 2.53 ng/mL; p = 0.042). CONCLUSION: In patients with asthma, treatment with high-doses of ICs is associated with reduced levels of salivary MUC5B. This effect can explain some of the effects of ICs on oral health.
Authors: Rashida Pramanik; Samira M Osailan; Stephen J Challacombe; David Urquhart; Gordon B Proctor Journal: Eur J Oral Sci Date: 2010-06 Impact factor: 2.612
Authors: Bernardino Alcázar Navarrete; Gerardo Gómez-Moreno; Antonio Aguilar-Salvatierra; Javier Guardia; Pedro José Romero Palacios Journal: J Oral Pathol Med Date: 2014-08-26 Impact factor: 4.253
Authors: Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor Journal: Am J Respir Crit Care Med Date: 2011-09-01 Impact factor: 21.405
Authors: Gerardo Gómez-Moreno; Antonio Aguilar-Salvatierra; Javier Guardia; Alejandro Uribe-Marioni; Maribel Cabrera-Ayala; Rafael Arcesio Delgado-Ruiz; José Luis Calvo-Guirado Journal: Depress Anxiety Date: 2012-11-01 Impact factor: 6.505
Authors: Tim Dijkema; Chris H J Terhaard; Judith M Roesink; Cornelis P J Raaijmakers; Petra A M van den Keijbus; Henk S Brand; Enno C I Veerman Journal: Radiat Oncol Date: 2012-06-15 Impact factor: 3.481